A big industry announcement took one of these stocks lower.
News & Analysis: Bausch Health Companies
A lawsuit over the company's top-selling drug caused investors to worry.
BHC earnings call for the period ending August 6, 2019.
The healthcare company reported especially strong sales growth in the second quarter for gastrointestinal drug Xifaxan.
It was one of the best-performing healthcare stocks last month. Two new product launches and a big debt repayment were the primary contributors.
Which of these fallen stars has the more compelling comeback story?
Despite pressure on the broader market, these stocks bucked the downtrend.
BHC earnings call for the period ending March 31, 2019.
Rising sales in its eye-care segment propelled the drugmaker to its best quarter since 2015.
These value stocks may not remain undervalued for long, so you might want to check them out now.